MIRA MIRA Pharmaceuticals
- 0.760
- -0.011-1.43%
MIRA Pharmaceuticals News
Sector Update: Health Care Stocks Retreat Wednesday Afternoon
Health care stocks were slipping Wednesday afternoon, with the NYSE Health Care Index falling 0.8% and the Health Care Select Sector SPDR Fund (XLV) down 0.9%. The iShares Biotechnology ETF (IBB) drop
MIRA Pharmaceuticals Enhances CEO's Compensation Package
Mira Pharmaceuticals Inc.: The US Drug Administration has specified that Mira-55, a novel oral drug analogue of cannabis, is not classified as a controlled substance
Mira Pharmaceuticals Inc.: The US Drug Administration has specified that Mira-55, a novel oral drug analogue of cannabis, is not classified as a controlled substance
Express News | Mira Pharmaceuticals Inc: Dea Rules Mira-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
MIRA Pharmaceuticals(MIRA.US) Officer Buys US$8,176 in Common Stock
$MIRA Pharmaceuticals(MIRA.US)$ Officer Aminov Erez purchased 8,700 shares of common stock on May 21, 2024 at an average price of $0.94 for a total value of $8,176.Source: Announcement What is stateme
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects. We Value MIRA At $16.50 Using Discontinued Cash Flow Analysts And A 20% Discount Rate.
Watching MIRA Pharmaceuticals; Zacks Small-Cap Research Says Co Is Creating A THC Analog That Has The Same Benefits As THC Without The Negative Side Effects. We Value MIRA At $16.50 Using Discontinued
MIRA Pharmaceuticals Discusses With Memorial Sloan Kettering To Collaborate On A Preclinical Cancer Pain Model Utilizing The Co's Novel Oral Ketamine Analog
Ketamir-2, the Company's novel oral ketamine analog in development, aims to provide a safe and effective alternative for managing cancer pain and associated depressionMIAMI, May 21, 2024 /PRNewswire/
Dow Falls Over 150 Points; Sohu Posts Q1 Loss
U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 150 points on Monday.The Dow traded down 0.43% to 39,831.18 while the NASDAQ rose 0.53% to 16,775.01. The
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Shares of Virios Therapeutics, Inc. (NASDAQ:VIRI) fell sharply during Monday's session after the company priced a $1.7 million public offering of 8.5 million shares of common stock at $0.20 per share.
Mira Pharmaceuticals Shares Are Trading Higher After the Company Said It Has Advanced New Preclinical Studies Using Ketamir-2 Towards Clinical Development.
Mira Pharmaceuticals Shares Are Trading Higher After the Company Said It Has Advanced New Preclinical Studies Using Ketamir-2 Towards Clinical Development.
Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
MIRA Pharmaceuticals, Inc. (NASDAQ: MIRA) ("MIRA" or the "Company"), a pre-clinical-stage pharmaceutical company focused on the treatment of...
MIRA Pharmaceuticals | 10-Q: Quarterly report
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
MIRA Pharmaceuticals Sees Positive Trial Results for Ketamir-2
By Chris Wack MIRA Pharmaceuticals said it saw positive results in its trial for Ketamir-2, a novel oral ketamine analog that could potentially deliver ultra-rapid antidepressant effects. The pre-cl
Mira Pharmaceuticals Highlights Preclinical Ketamir-2 Updates; Says Is Hopeful Results Will Enable Co. To File An NDA With FDA By End Of This Year
Mira Pharmaceuticals Highlights Preclinical Ketamir-2 Updates; Says Is Hopeful Results Will Enable Co. To File An NDA With FDA By End Of This Year
Mira Pharmaceuticals Q4 EPS $(0.19) Beats $(0.23) Estimate
Mira Pharmaceuticals (NASDAQ:MIRA) reported quarterly losses of $(0.19) per share which beat the analyst consensus estimate of $(0.23) by 17.39 percent.
GOEV, CHEK and MESO Among Pre-market Losers
12 Health Care Stocks Moving In Tuesday's After-Market Session
GainersApollomics (NASDAQ:APLM) stock rose 10.9% to $0.61 during Tuesday's after-market session. The market value of their outstanding shares is at $54.5 million. Cara Therapeutics (NASDAQ:CARA) share
Press Release: MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, Former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor PR Newswire MIAMI, March 21, 2024 A seasoned pharmaceutical industry executiv
12 Health Care Stocks Moving In Wednesday's After-Market Session
GainersMolina Healthcare (NYSE:MOH) stock moved upwards by 24.2% to $503.11 during Wednesday's after-market session. The company's market cap stands at $29.3 billion. Evoke Pharma (NASDAQ:EVOK) shares
Analysis
Price Target
No Data
